Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Titel:
Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Auteur:
Smith, Matthew Parker, Chris Saad, Fred Miller, Kurt Tombal, Bertrand Ng, Quan Sing Boegemann, Martin Matveev, Vsevolod Piulats, Josep Maria Zucca, Luis Eduardo Karyakin, Oleg Kimura, Go Matsubara, Nobuaki Nahas, William Carlos Nolè, Franco Rosenbaum, Eli Heidenreich, Axel Kakehi, Yoshiyuki Zhang, Amily Krissel, Heiko Teufel, Michael Shen, Junwu Wagner, Volker Higano, Celestia